Table 4 Selected FDA-approved drugs and... | American Society of Hematology

Table 4

Selected FDA-approved drugs and those in development targeting the TNF superfamily

Cytokine	Drug	Mechanism	Disease	Status
TNF-α	Infliximab	mAbs	RA, PA, psoriasis, ALS, ulcerative colitis,	Approved
			Crohn disease
	Etanercept	RD	RA, PA, psoriasis, ALS, juvenile RA	Approved
	Adalimumab	mAbs	RA, PA, psoriasis, ALS, juvenile RA, Crohn disease	Approved
	Certolizumab	mAbs	RA, Crohn disease	Approved
	Golimumab	mAbs	RA, PA, AS	Approved
	TNF-α kinoid	Vaccine*	RA, Crohn disease	Phase 2
	ESBA105	SC antibody	Anterior uveitis	Phase 2
	ART621	mAbs	RA, psoriasis	Phase 2
	ATN-103	Nanobody	RA	Phase 1
LT-β	Baminercept α	LT-βR-Ig	RA	Phase 2
OX40L	huMAb OX40L	mAbs	Asthma	Phase 2‡
CD40L	Dacetuzumab	mAbs	Multiple myeloma	Phase 1
			Lymphoma, large B-cell, diffuse lymphoma, NHL	Phase 2
	HCD122	mAbs	Multiple myeloma	Phase 1
			Follicular lymphoma	Phase 2‡
FasL	APO010	Fusion protein†	Solid tumors	Phase 1
CD27L	MDX-1411	mAbs	Kidney cancer	Phase 1‡
	MDX-1203	ADC	Renal cell carcinoma, NHL	Phase 1
CD30L	XmAb2513	mAbs	Hodgkin lymphoma, anaplastic large-cell lymphoma	Phase 1
	SGN-35	ADC	Hodgkin lymphomas	Phase 3‡
			Lymphoma, large-cell, anaplastic lymphoma, NHL	Phase 2
	MDX-1401	mAbs	Hodgkin lymphomas	Phase 1
4–1BBL	BMS-663513	mAbs	Advanced cancer	Phase 1
			Melanoma	Phase 2
TRAIL	Mapatumumab	mAbs	Colorectal, NHL, non−small-cell lung cancer	Phase 2
	Lexatumumab	mAbs	Kidney cancer, lymphoma, neuroblastoma, sarcoma	Phase 1
	CS-1008	mAbs	Malignancies, lymphoma	Phase 1
			Colorectal neoplasms, pancreatic, lung cancer	Phase 2
RANKL	Denosumab	mAbs	Low bone mass, low bone mineral density, osteopenia, osteoporosis	Phase 3‡
TWEAK	BIIB023	mAbs	RA	Phase 1
APRIL	Atacicept	Fusion protein†	RA	Phase 2
			SLE	Phase 3‡
BAFF	Atacicept	Fusion protein†	RA	Phase 2
	Benlysta	mAbs	Arthritis, rheumatoid, SLE	Phase 2
	LY2127399	mAbs	RA	Phase 2
LIGHT	Baminercept α	LT-βR-Ig	RA	Phase 2

Cytokine	Drug	Mechanism	Disease	Status
TNF-α	Infliximab	mAbs	RA, PA, psoriasis, ALS, ulcerative colitis,	Approved
			Crohn disease
	Etanercept	RD	RA, PA, psoriasis, ALS, juvenile RA	Approved
	Adalimumab	mAbs	RA, PA, psoriasis, ALS, juvenile RA, Crohn disease	Approved
	Certolizumab	mAbs	RA, Crohn disease	Approved
	Golimumab	mAbs	RA, PA, AS	Approved
	TNF-α kinoid	Vaccine*	RA, Crohn disease	Phase 2
	ESBA105	SC antibody	Anterior uveitis	Phase 2
	ART621	mAbs	RA, psoriasis	Phase 2
	ATN-103	Nanobody	RA	Phase 1
LT-β	Baminercept α	LT-βR-Ig	RA	Phase 2
OX40L	huMAb OX40L	mAbs	Asthma	Phase 2‡
CD40L	Dacetuzumab	mAbs	Multiple myeloma	Phase 1
			Lymphoma, large B-cell, diffuse lymphoma, NHL	Phase 2
	HCD122	mAbs	Multiple myeloma	Phase 1
			Follicular lymphoma	Phase 2‡
FasL	APO010	Fusion protein†	Solid tumors	Phase 1
CD27L	MDX-1411	mAbs	Kidney cancer	Phase 1‡
	MDX-1203	ADC	Renal cell carcinoma, NHL	Phase 1
CD30L	XmAb2513	mAbs	Hodgkin lymphoma, anaplastic large-cell lymphoma	Phase 1
	SGN-35	ADC	Hodgkin lymphomas	Phase 3‡
			Lymphoma, large-cell, anaplastic lymphoma, NHL	Phase 2
	MDX-1401	mAbs	Hodgkin lymphomas	Phase 1
4–1BBL	BMS-663513	mAbs	Advanced cancer	Phase 1
			Melanoma	Phase 2
TRAIL	Mapatumumab	mAbs	Colorectal, NHL, non−small-cell lung cancer	Phase 2
	Lexatumumab	mAbs	Kidney cancer, lymphoma, neuroblastoma, sarcoma	Phase 1
	CS-1008	mAbs	Malignancies, lymphoma	Phase 1
			Colorectal neoplasms, pancreatic, lung cancer	Phase 2
RANKL	Denosumab	mAbs	Low bone mass, low bone mineral density, osteopenia, osteoporosis	Phase 3‡
TWEAK	BIIB023	mAbs	RA	Phase 1
APRIL	Atacicept	Fusion protein†	RA	Phase 2
			SLE	Phase 3‡
BAFF	Atacicept	Fusion protein†	RA	Phase 2
	Benlysta	mAbs	Arthritis, rheumatoid, SLE	Phase 2
	LY2127399	mAbs	RA	Phase 2
LIGHT	Baminercept α	LT-βR-Ig	RA	Phase 2

RD indicates receptor derivative; SC, single-chain; PA, psoriatic arthritis; ALS, amyotrophic lateral sclerosis; AS, ankylosing spondylitis; ADC, antibody-drug conjugate; and NHL, non-Hodgkin lymphoma.

Vaccine composed of a keyhole limpet hemocyanin-hTNFα heterocomplex immunogen.

†

Recombinant fusion protein.

‡

Ongoing study.

View Large

This Feature Is Available To Subscribers Only